ProRx Pharma Expands to 6,888 Sq.-Ft. to Meet Drug Shortage Demand

• ProRx Pharma has expanded its facility to 6,888 sq.-ft., doubling its size to increase manufacturing capacity and enhance compliance.

• The company has strengthened its leadership team and partnered with an FDA compliance consulting firm to support its growth.

ProRx Pharma, a cGMP, 503B outsourcing facility, has expanded its operations to meet the growing demand for compounded medications, particularly those on the FDA’s drug shortage list. The company has doubled its existing pharmaceutical and manufacturing facility to a total of 6,888 sq.-ft., enabling it to triple its production capacity. The expansion will also improve operational processes and strengthen adherence to compounding lab Standard Operating Procedures (SOPs) and FDA regulations.

As part of its strategic growth, ProRx Pharma has appointed a new Vice President of Clinical Operations with 40 years of experience in 503A and 503B compounding, along with a new head of its Quality Assurance unit specializing in compliance and product safety. The company has also partnered with an FDA compliance consulting firm that brings more than 25 years of industry expertise.

In addition to its expanded facility and leadership team, ProRx Pharma remains focused on its core services, which include pharmaceutical testing, formulation development, clinical supplies, and FDA documentation for clinical trials. The company is an FDA-registered cGMP facility and is currently licensed to provide compounded medications in 25 states, with plans for further expansion.

“Compounding pharmacies play a critical role in the healthcare ecosystem in terms of meeting patients’ demands for more accessible and affordable medications,” said Kurt Lunkwitz, Chief Operating Officer at ProRx Pharma. “The new leadership team at ProRx not only has a wealth of industry experience, but also a shared vision for the company’s future.”